학술논문
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial
Document Type
Article
Author
Röllig, C.; Hase, J.; Bornhäuser, M.; Thiede, C.; von Bonin, M.; Schetelig, J.; Kramer, M.; Ehninger, G.; Serve, H.; Brandts, C.H.; Hüttmann, A.; Noppeney, R.; Müller-Tidow, C.; Krug, U.; Berdel, W.E.; Baldus, C.D.; Kunzmann, V.; Einsele, H.; Krämer, A.; Schäfer-Eckart, K.; Neubauer, A.; Burchert, A.; Giagounidis, A.; Krause, S.W.; Mackensen, A.; Aulitzky, W.; Herbst, R.; Hänel, M.; Kiani, A.; Frickhofen, N.; Kullmer, J.; Kaiser, U.; Link, H.; Geer, T.; Reichle, A.; Junghanß, C.; Repp, R.; Heits, F.; Dürk, H.; Klut, I.-M.; Illmer, T.; Schaich, M.; Parmentier, S.; Görner, M.
Source
In: The Lancet Oncology . (The Lancet Oncology, 2015, 16(16):1691-1699)
Subject
Language
English
ISSN
14745488
14702045
14702045